These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15600382)

  • 41. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
    Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The metabolic effects of antipsychotic medications.
    Newcomer JW; Haupt DW
    Can J Psychiatry; 2006 Jul; 51(8):480-91. PubMed ID: 16933585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 45. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].
    Aguilar E; Coronas R; Caixàs A
    Med Clin (Barc); 2012 Nov; 139(12):542-6. PubMed ID: 22841467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study.
    Dursun SM; Szemis A; Andrews H; Reveley MA
    J Psychiatry Neurosci; 1999 Nov; 24(5):453-5. PubMed ID: 10586536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of atypical antipsychotics on weight and serum lipid levels.
    Meyer JM
    J Clin Psychiatry; 2001; 62 Suppl 27():27-34; discussion 40-1. PubMed ID: 11806486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach.
    Lund BC; Perry PJ; Brooks JM; Arndt S
    Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Side effects of atypical antipsychotic drugs.
    Ananth J; Parameswaran S; Gunatilake S
    Curr Pharm Des; 2004; 10(18):2219-29. PubMed ID: 15281897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased cardiovascular risk with second-generation antipsychotic agent switches.
    Ried LD; Renner BT; McConkey JR; Bengtson MA; Lopez LM
    J Am Pharm Assoc (2003); 2006; 46(4):491-8; quiz 499-501. PubMed ID: 16913393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances.
    Lu ML; Lane HY; Lin SK; Chen KP; Chang WH
    J Clin Psychiatry; 2004 Jun; 65(6):766-71. PubMed ID: 15291653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
    Daumit GL; Goff DC; Meyer JM; Davis VG; Nasrallah HA; McEvoy JP; Rosenheck R; Davis SM; Hsiao JK; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Oct; 105(1-3):175-87. PubMed ID: 18775645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.
    eder-Ischia U; Ebenbichler C; Fleischhacker WW
    Essent Psychopharmacol; 2005; 6(2):112-7. PubMed ID: 15765795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Assessment of metabolic impairments inducted by atypical antipsychotics among schizophrenic patients].
    Gauthé M; Goldberger C; Olié JP; Lôo H; Gury C; Poirier MF
    Encephale; 2005; 31(1 Pt 1):18-23. PubMed ID: 15971636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weight gain with clozapine compared to first generation antipsychotic medications.
    Covell NH; Weissman EM; Essock SM
    Schizophr Bull; 2004; 30(2):229-40. PubMed ID: 15279042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unusual suspect for antipsychotic-induced diabetes.
    O'Neill MF
    Drug Discov Today; 2005 Oct; 10(20):1338. PubMed ID: 16253867
    [No Abstract]   [Full Text] [Related]  

  • 59. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.
    Henderson DC; Nguyen DD; Copeland PM; Hayden DL; Borba CP; Louie PM; Freudenreich O; Evins AE; Cather C; Goff DC
    J Clin Psychiatry; 2005 Sep; 66(9):1116-21. PubMed ID: 16187768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy.
    Nasrallah HA
    Am J Health Syst Pharm; 2002 Nov; 59(22 Suppl 8):S16-21. PubMed ID: 12455295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.